ArriVent BioPharma Reports Full Year 2025 Financial Results: Key Developments and Upcoming Milestones

Overview

ArriVent BioPharma, Inc. (Nasdaq: AVBP), a clinical-stage biopharmaceutical company with a focus on innovative cancer therapeutics, has released its financial results for the year ended December 31, 2025. The company also provided significant updates on its clinical pipeline, particularly around firmonertinib, a next-generation EGFR inhibitor, and its advancing antibody-drug conjugate (ADC) programs. As of year-end, ArriVent reported cash and investments of \$312.8 million, with a projected runway into the third quarter of 2027.

Key Pipeline Highlights

• Firmonertinib:
  • Phase 3 Pivotal Data Expected Mid-2026: The global pivotal Phase 3 FURVENT study evaluating firmonertinib as first-line therapy for EGFR exon 20 insertion mutant NSCLC is anticipated to deliver topline results in mid-2026. This is an event-driven study, and timelines may be further refined as the study progresses.
  • Enrollment in ALPACCA Study: In December 2025, ArriVent dosed the first patient in the pivotal Phase 3 ALPACCA study, investigating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant NSCLC.
  • Positive Phase 1b Data: In September 2025, final proof-of-concept data from the Phase 1b FURTHER trial showed clinically meaningful progression-free survival, CNS complete responses, and a manageable safety profile for firmonertinib in EGFR PACC mutant NSCLC. This is believed to be the first clinical dataset for EGFR inhibitors in this specific patient population.
  • FURVENT Study Enrollment Completed: Enrollment for the global pivotal Phase 3 FURVENT study in first-line NSCLC EGFR exon 20 insertion mutations was completed in early 2025.
  • Regulatory Milestone in China: In February 2026, the company’s partner, Shanghai Allist Pharmaceutical, received NMPA approval for firmonertinib in China for second-line treatment of EGFR exon 20 insertion mutant NSCLC.
• Antibody-Drug Conjugate (ADC) Pipeline:
  • Lead Candidate ARR-217: Ongoing Phase 1 dose escalation for ARR-217 (CDH17-targeted ADC) in gastrointestinal cancers. First patient dosed in March 2026, following FDA IND clearance.
  • Expansion of ADC Pipeline: Additional ADC candidates are expected to advance toward the clinic, expanding ArriVent’s reach beyond lung cancer into multiple solid tumor indications.
  • Upcoming IND Filing: U.S. IND filing for first-in-class ADC program ARR-002 anticipated in the first half of 2026, with preclinical data presentation planned at an upcoming conference.

Financial Highlights

• Strong Cash Position: Cash and investments of \$312.8 million as of December 31, 2025, are expected to fund operations into Q3 2027.
• Operating Expenses: Research and development expenses were \$153.4 million in 2025 (including a one-time upfront payment to Lepu Biopharma), up from \$79.0 million in 2024. General and administrative expenses were \$24.2 million in 2025, compared to \$15.3 million in 2024.
• Net Loss: ArriVent reported a net loss of \$166.3 million for 2025, compared to a net loss of \$80.5 million for 2024.

Important Clinical and Regulatory Milestones (Potential Share Price Movers)

• Upcoming Phase 3 Data Readouts: The mid-2026 topline data from the FURVENT Phase 3 trial for firmonertinib in EGFR exon 20 insertion mutant NSCLC is a critical catalyst and could have significant implications for ArriVent’s valuation and market prospects.
• ALPACCA Study Progress: Ongoing enrollment and future data from the ALPACCA study targeting PACC mutant NSCLC represent another near-term value driver.
• Regulatory Approvals: The recent NMPA approval in China for firmonertinib’s second-line indication is a material development, strengthening the company’s commercial prospects in a major oncology market.
• ADC Pipeline Expansion: The advancement of ARR-217, and the planned IND for ARR-002, signal a broadening pipeline and additional shots on goal for future growth.
• Financial Runway: The company’s projected cash runway through Q3 2027 reduces financing risk and supports execution of key trials and pipeline expansion.

Product and Market Insights

• Firmonertinib Profile: An oral, highly brain-penetrant, mutation-selective EGFR inhibitor active against both classical and uncommon EGFR mutations (including PACC and exon 20 insertions). Already approved in China for certain NSCLC populations.
• Regulatory Designations: Firmonertinib holds U.S. FDA Breakthrough Therapy and Orphan Drug designations for specific EGFR and HER2 mutant NSCLC, supporting expedited development and potential market exclusivity.
• Unmet Need: EGFR exon 20 insertion and PACC mutations represent underserved NSCLC subgroups with poor outcomes using current therapies—an area of high unmet need and commercial opportunity.

Conclusion

ArriVent BioPharma’s 2025 results and pipeline updates underscore a period of significant advancement, with multiple near-term clinical and regulatory catalysts that could materially impact shareholder value. The company’s strong cash reserves, robust lead program, and expanding oncology pipeline position it as a key player to watch in the precision oncology sector. Investors should closely monitor the upcoming Phase 3 data readouts, regulatory progress, and ADC pipeline developments, as these events are likely to drive future valuation and potential share price movements.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information provided is based on the company’s public filings and statements as of the date of publication and may be subject to change without notice.

View ArriVent BioPharma, Inc. Historical chart here